{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:13:23Z","timestamp":1790712803812,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":309,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinsp.2025.100842","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:43:31Z","timestamp":1763775811000},"page":"100842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["CRISPR\/Cas9\u2013mediated MMP-9 silencing inhibits bladder cancer T24 cell invasion and migration in vitro"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-113X","authenticated-orcid":false,"given":"Fabio Pescarmona","family":"Gallucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5624-3798","authenticated-orcid":false,"given":"Juliana Alves","family":"de Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-8508","authenticated-orcid":false,"given":"Nayara Izabel","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-5647","authenticated-orcid":false,"given":"Ruan Cesar Aparecido","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-722X","authenticated-orcid":false,"given":"Vanessa Ribeiro","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-5617","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2615-7730","authenticated-orcid":false,"given":"Katia Ramos Moreira","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-8370","authenticated-orcid":false,"given":"William Carlos","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-3597","authenticated-orcid":false,"given":"Sabrina Thalita","family":"dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinsp.2025.100842_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0002","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100842_bib0004","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100842_bib0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bju.12601","article-title":"Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base","volume":"114","author":"Smith","year":"2014","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100842_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100842_bib0007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jgo.2015.04.004","article-title":"Long-term results of a concomitant boost radiotherapy technique for elderly patients with muscle-\u0131nvasive bladder cancer","volume":"6","author":"Canyilmaz","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eururo.2011.07.066","article-title":"External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder","volume":"61","author":"Nuhn","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100842_bib0010","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100842_bib0011","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/j.clgc.2019.12.004","article-title":"Effects of bladder cancer on UK healthcare costs and patient health-related quality of life: evidence from the BOXIT trial","volume":"18","author":"Cox","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100842_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"issue":"18","key":"10.1016\/j.clinsp.2025.100842_bib0013","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinsp.2025.100842_bib0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bse0380021","article-title":"Matrix metalloproteinases in cancer","volume":"38","author":"Itoh","year":"2002","journal-title":"Essay Biochem"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2741\/s429","article-title":"Historical perspective of matrix metalloproteases","volume":"7","author":"AE","year":"2015","journal-title":"Front Biosci (Schol Ed)"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031251","article-title":"Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00240-004-0440-8","article-title":"Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer","volume":"33","author":"Morgia","year":"2005","journal-title":"Urol Res"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12307-017-0199-4","article-title":"Positive correlation between matrix metalloproteinases and epithelial-to-mesenchymal transition and its association with clinical outcome in bladder cancer patients","volume":"11","author":"Singh","year":"2018","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.clinsp.2025.100842_bib0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2490-12-18","article-title":"Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer","volume":"12","author":"Reis","year":"2012","journal-title":"BMC Urol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100842_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrurol.2011.44","article-title":"Matrix metalloproteinases and their clinical relevance in urinary bladder cancer","volume":"8","author":"Szarvas","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00345-020-03188-x","article-title":"Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer","volume":"39","author":"Srougi","year":"2021","journal-title":"World J Urol"},{"issue":"6096","key":"10.1016\/j.clinsp.2025.100842_bib0022","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100842_bib0023","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084311","article-title":"The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195\/497 cluster","volume":"9","author":"Itesako","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.clinsp.2025.100842_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914847","article-title":"The effect of gene editing by CRISPR-Cas9 of miR-21 and the indirect target MMP9 in metastatic prostate cancer","volume":"24","author":"Camargo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100842_bib0026","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1167\/iovs.13-13630","article-title":"MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair?","volume":"55","author":"De Groef","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0027","first-page":"29","article-title":"New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression","volume":"1825","author":"Bauvois","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"Supplement","key":"10.1016\/j.clinsp.2025.100842_bib0028","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.4103\/0973-1482.163761","article-title":"Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis","volume":"14","author":"Wu","year":"2018","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0029","doi-asserted-by":"crossref","first-page":"873","DOI":"10.7314\/APJCP.2013.14.2.873","article-title":"Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients","volume":"14","author":"Gunes","year":"2013","journal-title":"Asia Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100842_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1464-410X.2003.04020.x","article-title":"Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine","volume":"91","author":"Nutt","year":"2003","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100842_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(00)00522-X","article-title":"Effects of tumor necrosis factor-alpha and interferon-gamma on expressions of matrix metalloproteinase-2 and -9 in human bladder cancer cells","volume":"159","author":"Shin","year":"2000","journal-title":"Cancer Lett"},{"issue":"15","key":"10.1016\/j.clinsp.2025.100842_bib0032","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1158\/0008-5472.CAN-04-0925","article-title":"HB-EGF is a potent inducer of tumor growth and angiogenesis","volume":"64","author":"Ongusaha","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100842_bib0033","first-page":"1007","article-title":"Activation of matrix metalloproteinase-9 by TNF-alpha in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways","volume":"19","author":"Lee","year":"2008","journal-title":"Oncol Rep"},{"issue":"8","key":"10.1016\/j.clinsp.2025.100842_bib0034","first-page":"2290","article-title":"Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer","volume":"60","author":"Inoue","year":"2000","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.clinsp.2025.100842_bib0035","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1158\/0008-5472.CAN-08-0094","article-title":"Oct-3\/4 expression reflects tumor progression and regulates motility of bladder cancer cells","volume":"68","author":"Chang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinsp.2025.100842_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2022.111144","article-title":"In vitro and in vivo anti-tumor efficacy of krill oil against bladder cancer: involvement of tumor-associated angiogenic vasculature","volume":"156","author":"Kim","year":"2022","journal-title":"Food Res Int"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100842_bib0037","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s12032-010-9582-4","article-title":"CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer","volume":"28","author":"Xue","year":"2011","journal-title":"Med Oncol"},{"issue":"46","key":"10.1016\/j.clinsp.2025.100842_bib0038","doi-asserted-by":"crossref","first-page":"35944","DOI":"10.1074\/jbc.M109.091769","article-title":"Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides","volume":"285","author":"Dufour","year":"2010","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.clinsp.2025.100842_bib0039","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1158\/0008-5472.CAN-10-4552","article-title":"Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9","volume":"71","author":"Dufour","year":"2011","journal-title":"Cancer Res"},{"issue":"2\u20133","key":"10.1016\/j.clinsp.2025.100842_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1023047431869","article-title":"Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials","volume":"22","author":"Pavlaki","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100842_bib0041","first-page":"1101","article-title":"Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies","volume":"4","author":"Nemunaitis","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"5564","key":"10.1016\/j.clinsp.2025.100842_bib0042","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:48:11Z","timestamp":1790711291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593225002601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S1807593225002601"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100842","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9\u2013mediated MMP-9 silencing inhibits bladder cancer T24 cell invasion and migration in vitro","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100842"}}